Use of serum KL-6 level for detecting patients with restrictive allograft syndrome after lung transplantation
Berastegui García, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Gómez-Ollés, Susana (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias)
Mendoza-Valderrey, Alberto (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Pereira-Veiga, Thais (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Culebras Amigo, Mario (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Monforte, Víctor (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Sáez-Giménez, Berta (Hospital Universitari Vall d'Hebron. Institut de Recerca)
López-Meseguer, Manuel (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Sintes-Permanyer, Helena (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Ruiz de Miguel, Victoria (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Bravo Masgoret, Carles (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Sacanell, Judith (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Ramon, María-Antonia (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Romero, Laura (Hospital Universitari Vall d'Hebron)
Deu, Maria (Hospital Universitari Vall d'Hebron)
Román, Antonio (Román Broto) (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	KL-6 is an antigen produced mainly by damaged type II pneumocytes that is involved in interstitial lung disease. Chronic lung allograft dysfunction (CLAD) after lung transplantation (LT) is a major concern for LT clinicians, especially in patients with restrictive allograft syndrome (RAS). We investigated KL-6 levels in serum and bronchoalveolar lavage fluid (BALF) as a potential biomarker of the RAS phenotype. Levels of KL-6 in serum and BALF were measured in 73 bilateral LT recipients, and patients were categorized into 4 groups: stable (ST), infection (LTI), bronchiolitis obliterans syndrome (BOS), and RAS. We also studied a healthy cohort to determine reference values for serum KL-6. The highest levels of KL-6 were found in the serum of patients with RAS (918 [487. 8-1638] U/mL). No differences were found for levels of KL-6 in BALF. Using a cut-off value of 465 U/mL serum KL-6 levels was able to differentiate RAS patients from BOS patients with a sensitivity of 100% and a specificity of 75%. Furthermore, higher serum KL-6 levels were associated with a decline in Forced Vital Capacity (FVC) at 6 months after sample collection. Therefore, KL-6 in serum may well be a potential biomarker for differentiating between the BOS and RAS phenotypes of CLAD in LT recipients.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	PloS one, Vol. 15 (january 2020) , ISSN 1932-6203

DOI: 10.1371/journal.pone.0226488
PMID: 31929536

14 p, 1.1 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats